Heart Test Laboratories Inc. Common Stock (HSCS) - Net Assets
Based on the latest financial reports, Heart Test Laboratories Inc. Common Stock (HSCS) has net assets worth $4.18 Million USD as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.00 Million) and total liabilities ($1.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Heart Test Laboratories Inc. Common Stoc balance sheet liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.18 Million |
| % of Total Assets | 69.75% |
| Annual Growth Rate | -8.25% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1656.79 |
Heart Test Laboratories Inc. Common Stock - Net Assets Trend (2020–2025)
This chart illustrates how Heart Test Laboratories Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Heart Test Laboratories Inc. Common Stoc total assets for the complete picture of this company's asset base.
Annual Net Assets for Heart Test Laboratories Inc. Common Stock (2020–2025)
The table below shows the annual net assets of Heart Test Laboratories Inc. Common Stock from 2020 to 2025. For live valuation and market cap data, see Heart Test Laboratories Inc. Common Stoc (HSCS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | $205.17K | -97.20% |
| 2024-04-30 | $7.32 Million | +3073.75% |
| 2023-04-30 | $230.56K | +103.81% |
| 2022-04-30 | $-6.06 Million | -217.13% |
| 2021-04-30 | $-1.91 Million | -705.16% |
| 2020-04-30 | $315.55K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Heart Test Laboratories Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2900515700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.12K | 0.55% |
| Other Components | $76.33 Million | 37203.94% |
| Total Equity | $205.17K | 100.00% |
Heart Test Laboratories Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Heart Test Laboratories Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bernard Loisea
PA:ALDBL
|
$6.17 Million |
|
Zimtu Capital Corp
V:ZC
|
$6.17 Million |
|
Culpeo Minerals Ltd
AU:CPO
|
$6.18 Million |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
$6.18 Million |
|
Minaean SP Construction Corp
V:MSP
|
$6.16 Million |
|
Iceni Gold Ltd
AU:ICL
|
$6.16 Million |
|
Enova Mining Ltd
AU:ENV
|
$6.16 Million |
|
Djasa Ubersakti Tbk
JK:PTDU
|
$6.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heart Test Laboratories Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,317,301 to 205,171, a change of -7,112,130 (-97.2%).
- Net loss of 8,765,229 reduced equity.
- New share issuances of 1,147,578 increased equity.
- Other comprehensive income increased equity by 380,000.
- Other factors increased equity by 125,521.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.77 Million | -4272.16% |
| Share Issuances | $1.15 Million | +559.33% |
| Other Comprehensive Income | $380.00K | +185.21% |
| Other Changes | $125.52K | +61.18% |
| Total Change | $- | -97.20% |
Book Value vs Market Value Analysis
This analysis compares Heart Test Laboratories Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.20x to 8.87x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-04-30 | $9.52 | $1.94 | x |
| 2021-04-30 | $-57.63 | $1.94 | x |
| 2022-04-30 | $-182.46 | $1.94 | x |
| 2023-04-30 | $2.90 | $1.94 | x |
| 2024-04-30 | $20.76 | $1.94 | x |
| 2025-04-30 | $0.22 | $1.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heart Test Laboratories Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4272.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -201499.52%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 20.58x
- Recent ROE (-4272.16%) is below the historical average (-1387.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -1207.77% | -5937.99% | 0.03x | 6.20x | $-3.84 Million |
| 2021 | 0.00% | -9577.29% | 0.01x | 0.00x | $-2.26 Million |
| 2022 | 0.00% | -33592.57% | 0.01x | 0.00x | $-4.22 Million |
| 2023 | -2756.06% | -123384.27% | 0.00x | 14.26x | $-6.38 Million |
| 2024 | -90.27% | -35511.87% | 0.00x | 1.30x | $-7.34 Million |
| 2025 | -4272.16% | -201499.52% | 0.00x | 20.58x | $-8.79 Million |
Industry Comparison
This section compares Heart Test Laboratories Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $757,800,566
- Average return on equity (ROE) among peers: -54.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heart Test Laboratories Inc. Common Stock (HSCS) | $4.18 Million | -1207.77% | 0.43x | $6.17 Million |
| Abbott Laboratories (ABT) | $7.43 Billion | 32.93% | 0.95x | $152.62 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $18.77 Million |
| Aethlon Medical Inc (AEMD) | $-7.09 Million | 0.00% | 0.00x | $2.76 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $12.47 Million |
| Allurion Technologies, Inc. (ALUR) | $19.83K | -26.07% | 15.64x | $9.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $3.99 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.11 Billion |
| Apyx Medical Inc (APYX) | $2.22 Million | 4.46% | 0.72x | $153.68 Million |
About Heart Test Laboratories Inc. Common Stock
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting… Read more